Characterizing Trachoma Elimination Using Serology

Nature Communications

By 
Everlyn Kamau, 
Pearl Anne Ante-Testard, 
Sarah Gwyn, 
Seth Blumberg, 
Zeinab Abdalla, 
Kristen Aiemjoy, 
Abdou Amza, 
Solomon Aragie, 
Ahmed M. Arzika, 
Marcel S. Awoussi, 
Robin L. Bailey, 
Robert Butcher, 
E. Kelly Callahan, 
David Chaima, 
Adisu Abebe Dawed, 
Martha Idalí Saboyá Díaz, 
Abou-Bakr Sidik Domingo, 
Chris Drakeley, 
Belgesa E. Elshafie, 
Paul M. Emerson, 
Kimberly Fornace, 
Katherine Gass, 
E. Brook Goodhew, 
Jaouad Hammou, 
Emma M. Harding-Esch, 
PJ Hooper, 
Boubacar Kadri, 
Khumbo Kalua, 
Sarjo Kanyi, 
Mabula Kasubi, 
Amir B. Kello, 
Robert Ko, 
Patrick J. Lammie, 
Andres G. Lescano, 
Ramatou Maliki, 
Michael Peter Masika, 
Stephanie J. Migchelsen, 
Beido Nassirou, 
John M. Nesemann, 
Nishanth Parameswaran, 
Willie Pomat, 
Kristen K. Renneker, 
Chrissy Roberts, 
Prudence Rymil, 
Eshetu Sata, 
Laura Senyonjo, 
Fikre Seife, 
Ansumana Sillah, 
Oliver Sokana, 
Ariktha Srivathsan, 
Zerihun Tadesse, 
Fasihah Taleo, 
Emma Michelle Taylor, 
Rabebe Tekeraoi, 
Kwamy Togbey, 
Sheila K. West, 
Karana Wickens, 
Timothy William, 
Dionna M. Wittberg, 
Dorothy Yeboah-Manu, 
Mohammed Youbi, 
Taye Zeru, 
Jeremy D. Keenan, 
Thomas M. Lietman, 
Anthony W. Solomon, 
Scott D. Nash, 
Diana L. Martin, 
and Benjamin F. Arnold

Abstract

Trachoma is targeted for global elimination as a public health problem by 2030. Measurement of IgG antibodies in children is being considered for surveillance and programmatic decision-making. There are currently no programmatic guidelines based on serology, which represents a generalizable problem in seroepidemiology and disease elimination. Here, we collate Chlamydia trachomatis Pgp3 and CT694 IgG measurements from 48 serosurveys across Africa, Latin America, and the Pacific Islands (41,168 children ages 1–5 years) and propose a novel approach to estimate the probability that population C. trachomatis transmission is below or above levels requiring ongoing programmatic action. We determine that trachoma programs could halt control measures with >90% certainty when seroconversion rates (SCRs) are ≤2.2 per 100 person-years. Conversely, SCRs ≥4.5 per 100 person-years correspond with >90% certainty that further control interventions are needed. More extreme SCR thresholds correspond with higher levels of confidence of elimination (lower SCR) or ongoing action needed (higher SCR). This study demonstrates a robust approach for using trachoma serosurveys to guide elimination program decisions.

Related Resources

Read More
Read More
Read More